
Raimundo Goberna OrtÃ-z

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7758472/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of two HbA1c point-of-care analyzers. Clinical Chemistry and Laboratory Medicine, 2011, 49, 653-657.	1.4	29
2	Glycated hemoglobin vs. the oral glucose tolerance test for the exclusion of impaired glucose tolerance in high-risk individuals. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1719-1722.	1.4	11
3	MAPK and PI3K activities are required for leptin stimulation of protein synthesis in human trophoblastic cells. Biochemical and Biophysical Research Communications, 2010, 396, 956-960.	1.0	36
4	Leptin Stimulates Protein Synthesis-Activating Translation Machinery in Human Trophoblastic Cells1. Biology of Reproduction, 2009, 81, 826-832.	1.2	62
5	Leptin promotes cell survival and activates Jurkat T lymphocytes by stimulation of mitogen-activated protein kinase. Clinical and Experimental Immunology, 2008, 151, 505-518.	1.1	45
6	Leptin prevents apoptosis of trophoblastic cells by activation of MAPK pathway. Archives of Biochemistry and Biophysics, 2008, 477, 390-395.	1.4	73
7	Sam68 is tyrosine phosphorylated and recruited to signalling in peripheral blood mononuclear cells from HIV infected patients. Clinical and Experimental Immunology, 2005, 141, 518-525.	1.1	6
8	Educational intervention together with an on-line quality control program achieve recommended analytical goals for bedside blood glucose monitoring in a 1200-bed university hospital. Clinical Chemistry and Laboratory Medicine, 2005, 43, 876-9.	1.4	9
9	Expression of activation molecules in neutrophils, monocytes and lymphocytes from patients with unstable angina treated with stent implantation. Clinical Chemistry and Laboratory Medicine, 2004, 42, 273-8.	1.4	6
10	Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clinical and Experimental Immunology, 2003, 133, 11-19.	1.1	294
11	Leptin stimulates the oxidative burst in control monocytes but attenuates the oxidative burst in monocytes from HIV-infected patients. Clinical and Experimental Immunology, 2003, 134, 464-469.	1.1	45
12	Inflammatory Response to Coronary Stent Implantation in Patients with Unstable Angina. Clinical Chemistry and Laboratory Medicine, 2002, 40, 769-74.	1.4	14
13	Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. Journal of Nutritional Biochemistry, 2002, 13, 75-79.	1.9	76
14	Leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells byin vitroactivation andin vivoin HIV-infected patients. Clinical and Experimental Immunology, 2002, 129, 119-124.	1.1	56
15	Human Leptin Enhances Activation and Proliferation of Human Circulating T Lymphocytes. Cellular Immunology, 2000, 199, 15-24.	1.4	492
16	Human Leptin Stimulates Proliferation and Activation of Human Circulating Monocytes. Cellular Immunology, 1999, 194, 6-11.	1.4	522
17	Circadian variations in the rat serum total antioxidant status: Correlation with melatonin levels. Journal of Pineal Research, 1998, 25, 1-4.	3.4	63
18	Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. Journal of Neuroimmunology, 1998, 92, 76-84.	1.1	100

#	Article	IF	CITATIONS
19	Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels. Diabetes Care, 1998, 21, 1951-1954.	4.3	35
20	Pancreastatin Signaling in the Liver. , 1997, , 589-593.		1
21	Pancreastatin action in the liver: Dual coupling to different G proteins. Cellular Signalling, 1996, 8, 9-12.	1.7	28
22	Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension. Neuropeptides, 1995, 29, 97-101.	0.9	30
23	Highâ€affinity binding of melatonin by human circulating T lymphocytes (CD4 ⁺). FASEB Journal, 1995, 9, 1331-1335.	0.2	94
24	Diminished Insulin Receptors on Erythrocyte Ghosts in Nonobese Patients with Essential Hypertension Independent of Hyperinsulinemia. Journal of Cardiovascular Pharmacology, 1994, 24, 74-77.	0.8	8
25	Pancreastatin activates pertussis toxin-sensitive guanylate cyclase and pertussis toxin-insensitive phospholipase C in rat liver membranes. Journal of Cellular Biochemistry, 1994, 55, 173-181.	1.2	32
26	Pancreastatin inhibits insulin-stimulated glycogen synthesis but not glycolysis in rat hepatocytes. Regulatory Peptides, 1994, 51, 215-220.	1.9	36
27	Sensitivity of Insulin-Secreting RIN m5F Cells to Undergoing Apoptosis by the Protein Kinase C Inhibitor Staurosporine. Experimental Cell Research, 1993, 209, 160-163.	1.2	27
28	Pancreastatin decreases plasma epinephrine levels in surgical stress in the rat. Peptides, 1993, 14, 797-799.	1.2	16
29	Pancreastatin increases cytosolic Ca2+ in insulin secreting RINm5F cells. Molecular and Cellular Endocrinology, 1992, 88, 129-133.	1.6	23
30	Guanine nucleotide regulation of VIP binding to rat peritoneal macrophage membranes. Peptides, 1992, 13, 953-955.	1.2	15
31	Pancreastatin and its 33–49 C-terminal fragment inhibit glucagon-stimulated insulin in vivo. General Pharmacology, 1992, 23, 637-638.	0.7	19
32	Nucleotide regulation of vasoactive intestinal peptide binding to bovine thyroid plasma membranes. Bioscience Reports, 1990, 10, 519-525.	1.1	6
33	Glycogenolytic effect of pancreastatin in the rat. Bioscience Reports, 1990, 10, 87-91.	1.1	49
34	Decreased binding of vasoactive intestinal peptide to intestinal epithelial cells from hypothyroid rats. Biochemical and Biophysical Research Communications, 1989, 162, 701-707.	1.0	2
35	Interaction of vasoactive intestinal peptide (VIP) with rat lymphoid cells. Peptides, 1986, 7, 177-181.	1.2	62
36	The interaction of vasoactive intestinal peptide (VIP) with isolated bovine thyroid plasma membranes. Biochemical and Biophysical Research Communications, 1985, 128, 1336-1341.	1.0	13

#	Article	IF	CITATIONS
37	Activation of cyclic AMP-dependent protein kinase by VIP in blood mononuclear cells. Peptides, 1984, 5, 371-373.	1.2	30
38	The effect of different kinds of refeeding on islet glucose phosphorylating activities. Metabolism: Clinical and Experimental, 1984, 33, 1097-1101.	1.5	2
39	In vitro glucose reversal of the inhibitory effect of fasting on epinephrine-induced lipolysis. Biochemical and Biophysical Research Communications, 1981, 98, 15-20.	1.0	8
40	Interaction of vasoactive intestinal peptide with a cell line (HeLa) derived from human carcinoma of the cervix: Binding to specific sites and stimulation of adenylate cyclase. Molecular and Cellular Biochemistry, 1981, 37, 167-176.	1.4	13